Literature DB >> 35005430

Structural arrangement of the VH and VL domains in the COBRA™ T-cell engaging single-chain diabody.

Jessica Krakow1, Michal Hammel2, Ying Zhu1, Brian J Hillier1, Bryce Paolella1, Austin Desmarais1, Rusty Wall1, Tseng-Hui T Chen1, Rex Pei1, Chulani Karunatilake1, Robert DuBridge1, Maia Vinogradova1.   

Abstract

BACKGROUND: COBRA™ (COnditional Bispecific Redirected Activation) T-cell engagers are designed to target solid tumors as a single polypeptide chain prodrug that becomes activated by proteolysis in the tumor microenvironment. One COBRA molecule comprises seven Ig domains: three single-domain antibodies (sdAbs) recognizing a tumor target or human serum albumin (HSA), and CD3ε-binding variable fragment heavy chain (VH) and variable fragment light chain (VL) and their inactivated counterparts, VHi and VLi. Pairing of VH and VL, and VLi and VHi into single-chain variable fragments (Fv) is prevented by shortened inter-domain linkers. Instead, VH and VL are expected to interact with VLi and VHi, respectively, thus making a diabody whose binding to CD3ε on the T-cells is impaired.
METHODS: We analyzed the structure of an epidermal growth factor receptor (EGFR) COBRA in solution using negative stain electron microscopy (EM) and small-angle X-ray scattering (SAXS).
RESULTS: We found that this EGFR COBRA forms stable monomers with a very dynamic interdomain arrangement. At most, only five domains at a time appeared ordered, and only one VH-VL pair was found in the Fv orientation. Nonenzymatic posttranslational modifications suggest that the CDR3 loops in the VL-VHi pair are exposed but are buried in the VH-VLi pair. The MMP9 cleavage rate of the prodrug when bound to recombinant EGFR or HSA is not affected, indicating positioning of the MMP9-cleavable linker away from the EGFR and HSA binding sites.
CONCLUSION: Here, we propose a model for EGFR COBRA where VH and VLi form an Fv, and VL and VHi do not, possibly interacting with other Ig domains. SAXS and MMP9 cleavage analyses suggest that all COBRA molecules tested have a similar structural architecture.
© The Author(s) 2021. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  SAXS; T-cell engager; antibody; diabody; protein therapeutic; structure

Year:  2021        PMID: 35005430      PMCID: PMC8719580          DOI: 10.1093/abt/tbab028

Source DB:  PubMed          Journal:  Antib Ther        ISSN: 2516-4236


  25 in total

1.  Situs: A package for docking crystal structures into low-resolution maps from electron microscopy.

Authors:  W Wriggers; R A Milligan; J A McCammon
Journal:  J Struct Biol       Date:  1999 Apr-May       Impact factor: 2.867

2.  Analysis and prediction of VH/VL packing in antibodies.

Authors:  K R Abhinandan; Andrew C R Martin
Journal:  Protein Eng Des Sel       Date:  2010-06-30       Impact factor: 1.650

3.  High-throughput SAXS for the characterization of biomolecules in solution: a practical approach.

Authors:  Kevin N Dyer; Michal Hammel; Robert P Rambo; Susan E Tsutakawa; Ivan Rodic; Scott Classen; John A Tainer; Greg L Hura
Journal:  Methods Mol Biol       Date:  2014

4.  Comparative protein modelling by satisfaction of spatial restraints.

Authors:  A Sali; T L Blundell
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

5.  Domain association in immunoglobulin molecules. The packing of variable domains.

Authors:  C Chothia; J Novotný; R Bruccoleri; M Karplus
Journal:  J Mol Biol       Date:  1985-12-05       Impact factor: 5.469

6.  Chemically Programmed Bispecific Antibodies in Diabody Format.

Authors:  Even Walseng; Christopher G Nelson; Junpeng Qi; Alex R Nanna; William R Roush; Rajib K Goswami; Subhash C Sinha; Terrence R Burke; Christoph Rader
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

Review 7.  Bispecific T-cell engaging antibodies for cancer therapy.

Authors:  Patrick A Baeuerle; Carsten Reinhardt
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

8.  Determinants of the assembly and function of antibody variable domains.

Authors:  Eva Maria Herold; Christine John; Benedikt Weber; Stephan Kremser; Jonathan Eras; Carolin Berner; Sabrina Deubler; Martin Zacharias; Johannes Buchner
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

9.  Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.

Authors:  Adam R Root; Wei Cao; Bilian Li; Peter LaPan; Caryl Meade; Jocelyn Sanford; Macy Jin; Cliona O'Sullivan; Emma Cummins; Matthew Lambert; Alfredo D Sheehan; Weijun Ma; Scott Gatto; Kelvin Kerns; Khetemenee Lam; Aaron M D'Antona; Lily Zhu; William A Brady; Susan Benard; Amy King; Tao He; Lisa Racie; Maya Arai; Dianah Barrett; Wayne Stochaj; Edward R LaVallie; James R Apgar; Kristine Svenson; Lidia Mosyak; Yinhua Yang; Gurunadh R Chichili; Liqin Liu; Hua Li; Steve Burke; Syd Johnson; Ralph Alderson; William J J Finlay; Laura Lin; Stéphane Olland; William Somers; Ezio Bonvini; Hans-Peter Gerber; Chad May; Paul A Moore; Lioudmila Tchistiakova; Laird Bloom
Journal:  Antibodies (Basel)       Date:  2016-03-04

10.  COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.

Authors:  Anand Panchal; Pui Seto; Russell Wall; Brian J Hillier; Ying Zhu; Jessica Krakow; Aakash Datt; Elizabeth Pongo; Andisheh Bagheri; Tseng-Hui T Chen; Jeremiah D Degenhardt; Patricia A Culp; Danielle E Dettling; Maia V Vinogradova; Chad May; Robert B DuBridge
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.